Royalty Pharma plc(RPRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:31 AM ET (Korea 9/11 17:31)
Full metrics table
| Index | - | P/E | 31.27 | EPS (ttm) | 1.88 | Insider Own | 6.37% | Shs Outstand | 445.8M | Perf Week | -6.91% |
| Market Cap | 33.78B | Forward P/E | 10.25 | EPS next Y | 7.33% | Insider Trans | -1.63% | Shs Float | 416.9M | Perf Month | 1.66% |
| Enterprise Value | 44.86B | PEG | 1 | EPS next Q | 1.18 | Inst Own | 85.07% | Short Float | 2.78% | Perf Quarter | 7.76% |
| Income | 0.81B | P/S | 13.32 | EPS this Y | 10.62% | Inst Trans | 1.39% | Short Ratio | 3.74 | Perf Half Y | 25.83% |
| Sales | 2.54B | P/B | 3.83 | EPS next 5Y | 10.23% | ROA | 4.27% | Short Interest | 11.61M | Perf YTD | 52.04% |
| Book/sh | 15.33 | P/C | 40.36 | EPS past 3/5Y | 163.11% -7.26% | ROE | 12.36% | 52W High | -8.74% ($64.38) | Perf Year | 62.38% |
| Cash/sh | 1.46 | P/FCF | 11.22 | Sales past 3/5Y | 2.06% 2.3% | ROIC | 5.29% | 52W Low | 69.65% ($34.63) | Perf 3Y | 101.27% |
| Dividend Est. | $1.03 (1.76%) | EV/EBITDA | 28.29 | EPS Y/Y TTM | -18.25% | Gross Margin | 99.81% | Volatility(W/M) | 2.43% 2.21% | Perf 5Y | 52.68% |
| Dividend TTM | 0.92 | EV/Sales | 17.69 | Sales Y/Y TTM | 9.99% | Oper. Margin | 62.33% | ATR (14) | 1.62 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 2.8 | EPS Q/Q | -43.58% | Profit Margin | 32.13% | RSI (14) | 42.23 | Recom | 1.4 |
| Dividend Gr. 3/5Y | 5.01% 24.01% | Current Ratio | 2.8 | Sales Q/Q | 16.5% | SMA20 | -3.89% ($61.13) | Beta | 0.41 | Target Price | $65.71 |
| Payout | 49.4% | Debt/Eq | 1.31 | Earnings | 2026/8/5 | SMA50 | -0.68% ($59.15) | Rel Volume | 1.07 | Prev Close | $60.59 |
| Employees | 100 | LT Debt/Eq | 1.26 | EPS/Sales Surpr. | 3.82% 1.85% | SMA200 | 18.56% ($49.55) | Avg Volume(3M) | 3.10M | Price | $58.75 |
| IPO | 2020/6/16 | Option/Short | Yes/Yes | Trades | 30996 | Volume | 3,322,470 | Change | -3.04% |
Company
RPRX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Royalty Pharma is a licensing capital investment company that acquires royalty rights to revenue from new drugs and therapies from biotech and pharmaceutical companies to secure long-term cash flow. With a unique business model that does not bear the risks of in-house drug research and development while continuously receiving a share of the revenue from the global commercialization of new drugs, it manages a diversified royalty portfolio spanning various therapeutic areas.
Over the past 1 year, on the higher side
9% below its 1-year high.
RPRX makes money exceptionally well
62.33% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.6% this year.
Tap to view numbers
The price looks about right
Trading at 31.3 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +101.3% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 1.76% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 85.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
NMB 0.08%
IHE 0.04%
ELCV 0.03%
PBE 0.03%
OUSM 0.03%It ranks #4 in the industry
Based on market cap of $34B.
RPRX $34B PER 31.3
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is RPRX?
RPRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RPRX?
The market cap of RPRX is approximately $33.8B, ranking 430 within its sector.
Does RPRX pay dividends?
RPRX has a dividend yield of approximately 1.76%, with an annual dividend of $1.03.
What is the P/E ratio of RPRX?
RPRX has a P/E ratio of approximately 31.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RPRX?
RPRX has recorded a 52-week high of $64.38 and a low of $34.63.
